261 related articles for article (PubMed ID: 15681811)
1. The degeneration of dopamine neurons in Parkinson's disease: insights from embryology and evolution of the mesostriatocortical system.
Vernier P; Moret F; Callier S; Snapyan M; Wersinger C; Sidhu A
Ann N Y Acad Sci; 2004 Dec; 1035():231-49. PubMed ID: 15681811
[TBL] [Abstract][Full Text] [Related]
2. Ventral tegmental area dopamine neurons are resistant to human mutant alpha-synuclein overexpression.
Maingay M; Romero-Ramos M; Carta M; Kirik D
Neurobiol Dis; 2006 Sep; 23(3):522-32. PubMed ID: 16806952
[TBL] [Abstract][Full Text] [Related]
3. Response of the GABAergic and dopaminergic mesostriatal projections to the lesion of the contralateral dopaminergic mesostriatal pathway in the rat.
González-Hernández T; Barroso-Chinea P; Rodríguez M
Mov Disord; 2004 Sep; 19(9):1029-1042. PubMed ID: 15372592
[TBL] [Abstract][Full Text] [Related]
4. Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism.
Murray AM; Weihmueller FB; Marshall JF; Hurtig HI; Gottleib GL; Joyce JN
Ann Neurol; 1995 Mar; 37(3):300-12. PubMed ID: 7695230
[TBL] [Abstract][Full Text] [Related]
5. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
6. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
7. Genetic contributions to Parkinson's disease.
Huang Y; Cheung L; Rowe D; Halliday G
Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
[TBL] [Abstract][Full Text] [Related]
8. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons.
González-Hernández T; Barroso-Chinea P; De La Cruz Muros I; Del Mar Pérez-Delgado M; Rodríguez M
J Comp Neurol; 2004 Nov; 479(2):198-215. PubMed ID: 15452855
[TBL] [Abstract][Full Text] [Related]
9. Transplantation of autologous sympathetic neurons as a potential strategy to restore metabolic functions of the damaged nigrostriatal dopamine nerve terminals in Parkinson's disease.
Nakao N; Shintani-Mizushima A; Kakishita K; Itakura T
Brain Res Rev; 2006 Sep; 52(2):244-56. PubMed ID: 16644019
[TBL] [Abstract][Full Text] [Related]
10. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
Huot P; Lévesque M; Parent A
Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
[TBL] [Abstract][Full Text] [Related]
11. Enhanced glutamatergic phenotype of mesencephalic dopamine neurons after neonatal 6-hydroxydopamine lesion.
Dal Bo G; Bérubé-Carrière N; Mendez JA; Leo D; Riad M; Descarries L; Lévesque D; Trudeau LE
Neuroscience; 2008 Sep; 156(1):59-70. PubMed ID: 18706980
[TBL] [Abstract][Full Text] [Related]
12. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells.
Isacson O; Bjorklund LM; Schumacher JM
Ann Neurol; 2003; 53 Suppl 3():S135-46; discussion S146-8. PubMed ID: 12666105
[TBL] [Abstract][Full Text] [Related]
13. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
14. Dopamine transporter glycosylation correlates with the vulnerability of midbrain dopaminergic cells in Parkinson's disease.
Afonso-Oramas D; Cruz-Muros I; Alvarez de la Rosa D; Abreu P; Giráldez T; Castro-Hernández J; Salas-Hernández J; Lanciego JL; Rodríguez M; González-Hernández T
Neurobiol Dis; 2009 Dec; 36(3):494-508. PubMed ID: 19766189
[TBL] [Abstract][Full Text] [Related]
15. Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons.
Kim ST; Kim EM; Choi JH; Son HJ; Ji IJ; Joh TH; Chung SJ; Hwang O
Neurochem Int; 2010 Jan; 56(1):161-7. PubMed ID: 19815046
[TBL] [Abstract][Full Text] [Related]
16. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
17. Impact of grafted serotonin and dopamine neurons on development of L-DOPA-induced dyskinesias in parkinsonian rats is determined by the extent of dopamine neuron degeneration.
Carlsson T; Carta M; Muñoz A; Mattsson B; Winkler C; Kirik D; Björklund A
Brain; 2009 Feb; 132(Pt 2):319-35. PubMed ID: 19039008
[TBL] [Abstract][Full Text] [Related]
18. Relationship among alpha-synuclein accumulation, dopamine synthesis, and neurodegeneration in Parkinson disease substantia nigra.
Mori F; Nishie M; Kakita A; Yoshimoto M; Takahashi H; Wakabayashi K
J Neuropathol Exp Neurol; 2006 Aug; 65(8):808-15. PubMed ID: 16896314
[TBL] [Abstract][Full Text] [Related]
19. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
20. [Expression of the enzymes of dopamine synthesis in non-dopaminergic neurons: functional significance and regulation].
Ugriumov MV
Usp Fiziol Nauk; 2007; 38(4):3-20. PubMed ID: 18064905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]